Inmed Pharmaceuticals Inc. ( (INM) ) has released its Q1 earnings. Here is a breakdown of the information Inmed Pharmaceuticals Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InMed Pharmaceuticals Inc. is a pharmaceutical company based in British Columbia, Canada, focused on developing proprietary drug candidates and manufacturing rare cannabinoids for the health and wellness sector. The company recently released its earnings report for the quarter ended September 30, 2025, highlighting its ongoing financial performance and strategic initiatives. During this period, InMed reported sales of $1.12 million, with a gross profit of $403,159. However, the company also faced a net loss of $1.73 million, reflecting its continued investment in research and development and general administrative expenses. Despite these challenges, InMed maintains a cash position of $9.33 million, which is expected to support operations into the fourth quarter of 2026. Looking ahead, the company remains committed to advancing its pharmaceutical and commercial segments, with a focus on achieving key milestones and exploring strategic partnerships to enhance its financial stability and market presence.